The price of Nemaura Medical Inc. (NASDAQ:NMRD) shares last traded on Wall Street rose 43.90% to $0.59.
Based on available information, 1 analysts follow Nemaura Medical Inc. (NASDAQ:NMRD). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $2.50 and a low of $2.50, we find $2.50. Given the previous closing price of $0.41, this indicates a potential upside of 509.76 percent. NMRD stock price is now -29.88% away from the 50-day moving average and -50.69% away from the 200-day moving average. The market capitalization of the company currently stands at $17.92M.
Among analysts, 0 rate the stock a hold while 1 rate it a buy. Brokers who have rated the stock have averaged $2.50 as their price target over the next twelve months.
With the price target of $12, H.C. Wainwright recently initiated with Buy rating for Nemaura Medical Inc. (NASDAQ: NMRD).
A total of 49.07% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in NMRD stock. In total, there are 20 active investors with 3.50% ownership of the company’s stock.
A candlestick chart of Nemaura Medical Inc. (NASDAQ: NMRD) showed a price of $0.4900 on Thursday morning. During the past 12 months, Nemaura Medical Inc. has had a low of $0.41 and a high of $3.43. The fifty day moving average price for NMRD is $0.8389 and a two-hundred day moving average price translates $1.1837 for the stock.
The latest earnings results from Nemaura Medical Inc. (NASDAQ: NMRD) was released for Jun, 2023. According to the Medical Devices Company, earnings per share came in at -$0.09, beating analysts’ expectations of -$0.15 by 0.06. This compares to -$0.16 EPS in the same period last year. For the current quarter, analysts expect NMRD to generate $150k in revenue.
Nemaura Medical Inc.(NMRD) Company Profile
Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.
